Level B· Emerging clinical evidence with positive signalsClinical TrialEurope PMCOpen access

Recent advances and future directions in urinary system tissue engineering

Yuan J., Suo D., Li P., Zhao X., Wang H., Chen B.

Clinical Trial on Chronic Inflammation, published in Mater Today Bio (2025) — summary generated from the PubMed abstract.

Open my reading list
Level B· Emerging clinical evidence with positive signalsEvidence level of this study

Several human studies show positive signals, while research methods and sample sizes continue to develop.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Clinical Trial
Journal
Mater Today Bio (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40066078
PMCID
PMC11891153
DOI
10.1016/j.mtbio.2025.101600
Citations
6

Abstract (original English)

Recent advancements in tissue engineering offer promising solutions for the repair and reconstruction of the urinary system, particularly in cases of urinary organ injuries. Historically, autologous tissue grafts and allografts have been the primary options for repairing damaged tissues. However, these approaches often lead to complications such as immune rejection, donor site morbidity, and functional limitations. Tissue engineering provides a more sustainable alternative by leveraging the potential of cells, bioactive scaffolds, and growth factors to regenerate and repair damaged tissues. This approach aims not only to restore tissue structure but also to enhance functional recovery. Key challenges in the field include achieving adequate vascularization, overcoming immune responses, and ensuring long-term tissue integration. Recent innovations, such as 3D bioprinting, stem cell-based therapies, and the development of novel biomaterials, show great promise in addressing these challenges. This review explores the current state of tissue engineering applications in the urological system, focusing on the regeneration of the bladder, urethra, and kidneys. We discuss recent breakthroughs, ongoing clinical trials, and emerging technologies, as well as the potential for these approaches to improve clinical outcomes. Finally, we outline critical future directions of tissue engineering

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.

Evidence level

Several human studies show positive signals, while research methods and sample sizes continue to develop.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research